Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses. by Chiurchiù, V et al.
Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are
critical in modulating T cell responses
DALLI, JP
 
 
 
 
 
(c) The Authors, 2016
This is the author’s version of the work. It is posted here by permission of the AAAS for
personaluse, not for redistribution. The definitive version was published in Science
Translational Medicine on 24 Aug 2016: Vol. 8, Issue 353, pp. 353ra111, DOI:
10.1126/scitranslmed.aaf7483
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/16182
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
! 1!
Pro-resolving lipid mediators Resolvin D1, Resolvin D2 and Maresin 1 are 
critical in modulating T cell responses 
 
Valerio Chiurchiù1,2*, Alessandro Leuti1,2, Jesmond Dalli3, Anders Jacobsson4, 
Luca Battistini5, Mauro Maccarrone1,2#, Charles N. Serhan3#* 
 
1Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy 
2European Center for Brain Research, Laboratory of Neurochemistry of Lipids, 
IRCCS Santa Lucia Foundation, Rome, Italy 
3Center for Experimental Therapeutics and Reperfusion Injury, Department of 
Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital 
and Harvard Medical School, Boston, Massachusetts, United States  
4Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm 
University, SE-10691 Stockholm, Sweden 
5European Center for Brain Research, Neuroimmunology Unit, IRCCS Santa Lucia 
Foundation, Rome, Italy 
 
 
 
# Equally senior authors 
 
*Address correspondence to:  
!
Dr. Valerio Chiurchiù, European Center for Brain Research, IRCCS Santa Lucia 
Foundation, via del Fosso di Fiorano 64, 00143, Rome, Italy. Tel.: +39 06 50170 
3223; fax: +39 06 50170 3334; email: v.chiurchiu@hsantalucia.it.!
 
Prof. Charles N. Serhan, Harvard Institutes of Medicine, 77 Ave. Louis Pasteur, HIM 
829, Boston, MA 02115, United States. Tel.: +1 617 525 5001; fax: +1 617 525 5017; 
e-mail: cnserhan@zeus.bwh.harvard.edu. 
 
 
OVERLINE: INFLAMMATION 
 
SINGLE SENTENCE SUMMARY 
Specialized pro-resolving lipid mediators resolvin D1, resolvin D2 and maresin 1 
reduce CD8 and CD4 cell activation as well as prevent Th1 and Th17 cell 
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differentiation from naïve T cells via GPR32 and ALX/FPR receptors while 
promoting de novo Treg induction via GPR32 receptor. 
 
EDITOR’S SUMMARY:  
TBD. 
 
ABSTRACT 
Resolution of inflammation is a finely regulated process mediated by specialized pro-
resolving lipid mediators (SPMs) including docosahexaenoic acid (DHA)-derived 
resolvins and maresins. The immunomodulatory role of SPMs in adaptive immune 
cells is of interest. Here, we report that the D-series resolvins Resolvin D1 and 
Resolvin D2 and Maresin 1 modulate adaptive immune responses in human peripheral 
blood lymphocytes.  These lipid mediators reduce cytokine production by activated 
CD8 T cells and CD4 T-helper (TH) 1 and TH17 cells, but do not modulate T cell 
inhibitory receptors or abrogate their capacity to proliferate.  Moreover, these SPMs 
prevented naïve CD4 T-cell differentiation into TH1 and TH17 by downregulating 
their signature transcription factors, T-bet and Rorc, in a mechanism mediated by the 
GPR32 and ALX/FPR2 receptors; they concomitantly enhanced de novo generation 
and function of Foxp3+ regulatory T (Treg) cells via the GPR32 receptor. These 
results were also supported in vivo in a mouse deficient for DHA synthesis (Elovl2-/-) 
that showed an increase in TH1/TH17 cells and a decrease in Treg cells compared to 
wild type mice. Additionally, either DHA supplementation in Elovl2-/- mice or in vivo 
administration of Resolvin D1 significantly reduced cytokine production upon 
specific stimulation of T cells. These findings demonstrate actions of specific SPMs 
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on adaptive immunity and provide a new avenue for SPM-based approaches to 
modulate chronic inflammation. 
 
INTRODUCTION 
Acute inflammation is generally protective for the host and is mediated by a plethora 
of well-known chemical messengers including cytokines, chemokines and lipid-
derived mediators (mostly produced from the essential fatty acid arachidonic acid) 
released by innate immune cells (1-3). Resolution of inflammation is a finely 
orchestrated active process governed by temporally and spatially regulated synthesis 
of local mediators that act in concert to reestablish tissue homeostasis after injury and 
phlogistic processes (for recent review see reference 4). The resolvins (Rvs), 
protectins (PDs), maresins (MaRs) and lipoxins (LXs), often referred together as 
specialized pro-resolving lipid mediators (SPMs) given their functions (4), are novel 
families of autacoids with a central role in resolving processes, which act as local 
mediators controlling the magnitude and extent of inflammatory events.  
SPMs are produced mainly by macrophages and neutrophils via separate pathways 
from omega-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) – the former yielding E-series Rvs and the latter D-
series Rvs, MaRs and PDs – as well as from omega-6 PUFA arachidonic acid (AA), 
which gives rise to LXs, via the action of lipoxygenases ALOX-5, ALOX-12, ALOX-
15 and cyclooxygenase COX-2. (5-8). These SPMs have received considerable 
attention in recent years because of their ability to stereoselectively regulate and 
reduce inflammatory conditions in animal disease models (4). Thus, SPMs prevent 
inflammation from spreading and halt the transition from acute to chronic. Yet, 
published studies focus almost exclusively on acute conditions and innate immunity 
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and, little is currently known about their possible action on the cellular components of 
adaptive immunity. This includes the finding that Resolvin E1 induces apoptosis of 
activated T cells and Protectin D1 reduces T-cell migration (9, 10). The present study 
investigated the selective actions of D-Series resolvins and Maresin 1, major SPMs 
that were recently found in human lymphoid tissues including human spleen and 
lymph nodes (11). Hence, we focused either on circulating CD8+ and CD4+ T 
lymphocytes and on CD4+ subsets, which include highly pathogenic T helper (TH) 
TH1 and TH17 cells, as well as regulatory T (Treg) lymphocytes. These results 
document the pivotal role(s) for specific SPMs in the control of adaptive immunity, 
thus providing a better understanding of the impact of these potent new bioactive lipid 
mediators on the spectrum of immune cells, and ultimately setting the standard for the 
potential development of new treatments for chronic inflammatory diseases.  
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RESULTS 
Pro-resolving lipid mediators modulate CD8+ and CD4+ T cell responses. 
Although data on SPMs mostly focuses on innate immune cells involved in the 
resolution of acute inflammation (4), we hypothesized that the several SPMs, 
specifically RvD1, RvD2, and MaR1 (Fig. 1A) could also affect the immune 
responses of adaptive immune cells. To test this hypothesis, initial studies were 
performed to assess whether increasing concentrations of RvD1, RvD2, and MaR1 (in 
the 1-100 nmol/L physiological range, 12) could affect the production of TNF-α from 
human CD8+ and CD4+ T lymphocytes (Fig. 1B). Both T cell subsets when activated 
with PMA/Ionomycin produced high amounts of intracellular TNF-α (Fig. 1C and 
1D), which was reduced upon pretreatment with all SPMs tested (Fig. 1D). Each of 
the specific mediators inhibited TNF-α production in a dose-dependent manner, and 
substantially reduced cytokine production at doses as low as 10.0 nmol/L. The lowest 
dose tested (1.0 nmol/L) only showed a slight and non-significant reduction of TNF-α 
production from both T cell subsets (Fig. 1D). The same result was also observed 
with an epimer of another newly discovered resolvin, the aspirin-triggered resolvin 
D3 (AT-RvD3), which dose-dependently reduced TNF-α production from both CD8+ 
and CD4+ T cells and was significant (p < 0.05) as low as 10 nmol/L (Fig. S1A). For 
this reason, in all further experiments, SPMs were used at the lowest effective 
concentration of 10.0 nmol/L. These initial results suggested that SPMs might indeed 
be effective in modulating adaptive immune responses.  
We next ascertained the possible impact of these SPMs (at 10 nmol/L) on the 
production of the specific cytokines that characterize the main proinflammatory T cell 
subsets, i.e. cytotoxic CD8+ T cells and CD4+ T helper-1 (TH1) and T helper-17 
(TH17) cells. Indeed, PMA/Ionomycin-activated CD8+ T cells produced high amounts 
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of TNF-α and IFN-γ, which were strongly reduced by each of these SPMs (Fig. 2A). 
Furthermore, the production of both IFN-γ and IL-17 from PMA/Ionomycin-activated 
CD4+ T cells was also strongly reduced by incubation with these SPMs (Fig. 2B). 
Interestingly, the ability of the different SPMs to suppress cytokine production from 
CD8+ T cells and CD4+ T cells was independent of the chemical class, suggesting 
that distinct lipid mediators are able to similarly modulate adaptive immune cells. 
Since the cytokine profile of human T cells may be differently determined depending 
on the assay and conditions used, we further investigated the immunomodulatory role 
of RvD1, RvD2 and MaR1 using a more specific and physiological stimulus for 
activating T cells, i.e. polyclonal activation of the T-cell receptor with anti-CD3 and 
anti-CD28. Cytokine production after stimulation of T cells with anti-CD3/CD28 was 
almost identical to that of PMA/ionomycin stimulation, even if intracellular levels of 
cytokines were lower, as expected (13) (Fig, 2C and 2D). In particular, RvD1, RvD2 
and MaR1 significantly (p < 0.05) reduced the capability of CD8+ T cells to produce 
TNF-α and IFN-γ (Fig. 2C) and that of CD4+ T cells to produce TNF-α (p < 0.05), 
IFN-γ (p < 0.01) and IL-17 (p < 0.01) (Fig. 2D), overall suggesting that SPMs might 
regulate TH1 and TH17 responses. 
 
SPMs regulate IL-2 production from T cells without affecting their viability - The 
immunomodulatory activity of D-series resolvins and MaR1 on T cell responses was 
also demonstrated by reduction of the crucial growth factor IL-2 compared with IL-2-
producing anti-CD3/anti-CD28-activated CD8+ and CD4+ T cells (Fig. 3A).  This 
effect was not due to an induction of cell death, as assessed by annexin-V staining 
that was used as a marker for apoptosis in combination with PI, in order to distinguish 
between apoptotic and necrotic cells. As expected, resting T cells were all annexin-V 
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and PI negative, whereas ~20% of anti-CD3/CD28-activated T cells were apoptotic 
(annexin-V positive) (Fig. 3B). Almost no variation in live cells (annexin-V and PI 
negative), early apoptosis (annexin-V positive and PI negative), late apoptosis 
(annexin-V and PI positive), or necrosis (PI positive and annexin-V negative) could 
be detected in RvD1-, RvD2- and MaR1-treated activated T cells, either on the total 
CD3+ T cell population (Fig. 3B upper panel) or in CD8+ or CD4+ T cells (Fig. 3B 
lower panel). Even after 24h of treatment, no significant increase in the proportion of 
total apoptotic cells was observed in both CD8+ and CD4+ T cells treated with the 
different SPMs compared to activated cells, although general cell viability showed a 
~50% decrease (Fig. S1B). SPMs treatment of resting T cells did not induce 
apoptosis, ruling out a potential cytotoxic role of these SPMs (Fig. S1C). 
Interestingly, the decrease in IL-2 did not result in a significant decrease in T cell 
proliferation, (Fig. 3C) nor was it associated with an altered cell-surface expression of 
several inhibitory receptors, including FasL, PD-1 and CTLA4 (Fig. 3D). 
 
SPMs critically affect TH1/TH17 and Treg differentiation - TH1 and TH17 subsets in 
peripheral blood are both derived from naïve CD4+ T cells upon antigen stimulation 
and specific skewing cytokines (14). Since both classes of SPMs dampened the 
inflammatory response of TNF-α- and IFN-γ-producing TH1 cells, and of IL-17-
producing TH17 cells from peripheral blood mononuclear cells, we next investigated 
whether RvD1, RvD2 or MaR1 were able to directly affect their differentiation from 
naïve CD4+ T cells into TH1 and TH17 lineages. To this aim, a standard naïve CD4+ 
T cells differentiation assay was performed by polyclonal stimulation with anti-
CD3/CD28, and specific polarizing cytokines in the presence of RvD1, RvD2 or 
MaR1 (Fig. 4A).  
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Under specific polarizing conditions, highly purified naïve CD4+ T cells displayed 
significantly higher amounts of intracellularly produced and extracellularly released 
IFN-γ (TH1) (p < 0.05) and IL-17 (TH17) (p < 0.01), as compared to non-polarized 
(TH0) cells (Fig. 4B and 4C). Furthermore, TH17 cells produced less IFN-γ, while TH1 
cells produced very low levels of IL-17, confirming previous data showing that the 
TH17 cytokine profile overlaps with TH1 cells (15). RvD1, RvD2 and MaR1 all 
affected TH1 and TH17 polarization (Fig. 4B and 4C). In particular, in non-skewed 
TH0 cells, which produce very low levels of both IFN-γ and IL-17, RvD1, RvD2 and 
MaR1 induced a slight and not significant decrease in both cytokines (Fig. S2), 
whereas they significantly reduced TH1 and TH17 generation, acting on both 
intracellular production (Fig. 4B) and extracellular release (Fig. 4C) of IFN-γ (p < 
0.05) from TH1 cells and that of IL-17 (p < 0.01) and IFN-γ (p < 0.05) from TH17 
cells. Next, to address whether TH1 and TH17 polarization was associated with the 
acquisition of their typical features, we also measured the mRNA encoding for the 
transcription factors known to be critical for their differentiation, T-bet and RORc, 
respectively. As expected, TH1 and TH17 conditions induced the highest expression of 
their specific transcription factors. The presence of RvD1, RvD2 or MaR1 during 
TH1/TH17 polarization led to decreased T-bet in TH1 cells and RORc in TH17 cells, 
with D-series resolvins being more effective than MaR1 (Fig. 4D). These findings 
support a pivotal role for SPMs also in hindering de novo TH1/TH17 differentiation. 
Of note, these SPMs also slightly increased intracellular IL-4 production (Fig. 4B) but 
not its extracellular release (Fig. 4C) while they decreased the signature TH2 
transcription factor GATA-3 (Fig. 4D).  
In order to obtain some in vivo evidence for the role of SPMs in reducing TH1 and 
TH17 responses, we analyzed the ability of these cells to express IFN-γ and IL-17 in 
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mice deficient for elongase 2 (Elovl2-/-), the key enzyme involved in the synthesis of 
DHA (the precursor of D-series resolvins and maresins) from EPA. Elovl2-/- mice 
have significantly reduced DHA levels and increased levels of DHA precursors, 
including EPA (16). As shown in Fig. 4E, splenic T cells produce higher amounts of 
IFN-γ and IL-17 in Elovl2-/- mice compared to wild type (WT) control mice and this 
was reversed following DHA supplementation, suggesting that in absence of the 
precursor of D-series resolvins and maresins, TH1 and TH17 responses are 
exacerbated. In order to further corroborate the in vivo role of SPMs in reducing T 
cell activation, intraperitoneal administration of RvD1 (100 ng per mouse) together 
with anti-CD3 (50 µg per mouse) significantly reduced the percentage of IFN-γ and 
IL-17 production (p < 0.05) from peripheral blood CD4+ T cells (Fig. 4F) in both WT 
and Elovl2-/- mice, whereby the latter showed increased cytokine production. 
Together these results suggest that the anti-inflammatory actions of SPMs at 
physiological doses on TH1 and TH17 cells are also demonstrable in vivo.  
In light of the role of SPMs in resolving inflammation and since regulatory T (Treg) 
cells are an important cell subset involved in modulating and maintaining self-
regulation of the immune system, we also investigated if SPMs could affect the 
generation of induced Treg (iTreg) cells. This cell subset develops from naïve CD4+ 
T cells upon antigen stimulation and TGF-β exposure (17). To this aim, highly 
purified naïve CD4+ T cells were cultured under Treg-inducing conditions in the 
presence of RvD1, RvD2, and MaR1 (all at 10 nmol/L) (Figure 5A). We found that 
each of these SPMs potentiated iTreg differentiation, with the lipids significantly 
enhancing Foxp3 expression compared to control iTreg cells (Fig. 5B) (p < 0.05 for 
RvD2 and p < 0.01 for RvD1 and MaR1). SPM-induced de novo generation of Treg 
cells was also paralleled by their capacity to increase their suppressive marker CTLA-
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4 and IL-10 release (p < 0.05), although they were incapable of modulating granzyme 
B production (Fig. 5B), suggesting that SPMs not only affect Treg induction but also 
impact specific functional properties. This action was further supported by in vivo 
evidence that Elovl2-/- mice have significantly lower levels (p < 0.05) of Foxp3+ Treg 
cells (identified as shown in Fig. S3) compared to WT mice, levels that were restored 
in DHA-supplemented mice (Fig. 5C).  
 
The actions of SPMs on T cells is mediated by GPR32 and ALX/FPR2 receptors - In 
order to verify whether SPMs-induced effects were associated with a higher CD4+ T 
cell response and to ascertain the molecular mechanism behind the 
immunomodulatory role of these lipid mediators on T cells, we sought to investigate 
the involvement of SPMs receptors in the effects we observed on TH1, TH17 and 
iTreg cells. Since we still possess limited information regarding the full spectrum of 
receptors engaged by the different classes of SPMs, we focused on the known 
receptors for D-series resolvins, GPR32 and ALX/FPR2 (18, 19). In Fig. 6 (left 
panels) we show that TH1 cells displayed the highest mRNA expression of both 
GPR32 and ALX/FPR2 compared to TH0 cells, whereas TH17 cells and TH2 showed 
similar levels of GPR32 and lower levels of ALX/FPR2. Furthermore, iTreg cells 
expressed very low levels of both receptors. Interestingly, the levels of GPR32 were 
higher in all the T cell subsets compared to ALX/FPR2, whereas iTreg cells showed a 
similar expression to TH0 cells. Immunoblotting analysis demonstrated that all T 
helper subsets express both GPR32 and ALX/FPR2, showing SPMs receptors 
expression on T cells. In particular TH1, TH17 and iTregs showed significantly higher 
(p < 0.05) levels of GPR32 with respect to TH0, whereas the expression of this 
receptor in TH2 cells was similar to that of TH0 control group (Fig. 6A, middle 
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panels). Conversely, ALX/FPR2 showed no differential expression and remained 
unchanged among all T cell subsets. Flow cytometry analysis also revealed increased 
expression of both receptors on CD3/CD28-activated total peripheral CD3 T cells 
(Figure 6A, right panels).  
Since these two G protein-coupled receptors are currently the only known receptors 
for RvD1, we next sought to verify their possible role as mediators of the observed 
effect of this pro-resolving lipid on T cells. Pre-incubation with anti-GPR32 or anti-
ALX/FPR2 neutralizing antibodies alone or in combination abrogated the suppressive 
activity of RvD1 on TH1 and TH17, as well as its enhancing activity on iTreg 
lymphocytes. In particular, the single neutralization of either GPR32 or ALX/FPR2 
significantly counteracted the inhibitory action of RvD1 on both PBMC-derived 
(Figure 6B) and de novo-generated TH1 and TH17 cells (Figure 6C) (p < 0.05), 
whereas the inactivation of both receptors was more potent, completely restoring the 
intracellular levels of IFN-γ and IL-17 as to those of activated T cells (Figures 6B and 
C), suggesting that the role of these two receptors might be additive. Conversely, the 
RvD1-induced de novo generation of Foxp3+ iTregs was specifically and 
significantly counteracted when neutralizing only GPR32 (p < 0.05) and not 
ALX/FPR2 (Figure 6C), also confirmed by the evidence that the neutralization of 
both receptors was not additive.  
 
 
 
 
 
 
! 12!
DISCUSSION 
Since their first identification 15 years ago, SPMs, which include resolvins, protectins 
and maresins, have proven to act as initiators of resolution programs of acute 
inflammation, thereby reducing granulocyte trafficking and the production of 
cytokines and extracellular reactive oxygen species, as well as by lowering the 
magnitude of the overall inflammatory response by enhancing macrophage-mediated 
clearance of cellular debris and invading microbes (4). Although the role of each of 
the SPMs is highly associated with the resolution of acute inflammation operated by 
cells of innate immunity, it is becoming increasingly clear that these bioactive lipids 
might take part also in the control of chronic inflammation, possibly via acting on 
cells of adaptive immunity (20-23). In this regard, little systematic evidence for a 
direct role of these resolving mediators on the distinct adaptive cell populations has 
been assessed (24, 25).  
In the present study, we interrogated the adaptive immune responses to specific SPMs 
that have not been addressed earlier. Cytotoxic CD8+ T cells eliminate neoplastic, 
infected or damaged cells mainly through the release of cytotoxins (perforin, 
granzymes and granulysins), and potentiate innate immune responses (macrophages 
and NK cells) through the release of cytokines such as IFN-γ and TNF-α (26). The 
observed ability of SPMs to dampen cytokines from CD8+ cells suggest that their role 
in resolving inflammation is exerted not only directly by clearing and blunting the 
responses of those innate immune cells during acute inflammation, but also indirectly 
by avoiding further recruitment or activation of innate cells, thus avoiding the onset of 
chronic inflammation or immune-mediated damage. Furthermore, CD8+ cells are also 
able to prime naïve and restimulate experienced CD4+ T cells to release high levels of 
helper cytokines (27). TH cells develop from naïve CD4+ T cells and differentiate into 
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specialized TH subsets after encountering foreign or auto-antigens (14, 28). However, 
persistent or uncontrolled TH cell responses are often associated with pathological 
states and tissue damage. In particular, excessive and/or abnormal TH1 and TH17 cell 
responses are involved in chronic inflammation and mediate several autoimmune 
diseases, including multiple sclerosis, rheumatoid arthritis, and psoriasis (29).  
Our present results reveal that specific SPMs, namely RvD1, RvD2 and MaR1, not 
only can directly modulate the inflammatory responses of already existing and 
activated TH1 and TH17 cells, but can also critically prevent their generation from 
naïve CD4+ T cells acting on their transcription factor-induced activation programs. 
Additionally, SPMs are able to enhance the differentiation of CD4+ T cells into Treg 
cells. Since Treg cells typically serve to dampen excessive immune responses, these 
cells play an important role in preventing the over-activation of TH1 and TH17 cells. 
This result is in line with the very recent report of MaR1 in engaging Treg cells in 
mice to promote resolution of lung inflammation (30). Although further studies are 
needed to demonstrate the existence of an indirect modulation of TH1 and TH17 cells 
by a SPM-mediated sustained induction of Treg cells, these findings suggest that 
SPMs might modulate inflammatory responses via several selective mechanisms on 
specific adaptive immune cells. This hypothesis is conceivable, also in the light of the 
recent discovery that TH17 cells transdifferentiate into Treg cells during resolution of 
inflammation (31), where SPMs might be possible key players of such TH17 
instability and plasticity.  
TH2 lymphocytes were relatively unresponsive to SPMs treatment under the 
conditions tested, in that none of the pro-resolving mediators tested regulated the 
generation of mature effector cells or cytokine release. These results are aligned with 
recent papers reporting that, in TH2-driven pathologies and mouse models, DHA-
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derived SPMs like RvD1 and PD1 do not affect IL-4 release and might ameliorate 
clinical outcome by acting on different targets than TH2 cells (32-35). Conversely, 
RvE1, which is derived from EPA, facilitates resolution of TH2-mediated asthmatic 
airway inflammation and atopic dermatitis by reducing TH2 cytokines (29, 36, 37). 
Our findings are also supported by the in vivo evidence that mice incapable of 
producing DHA-derived SPMs have higher numbers of hyperactive TH1 and TH17 
cells and concomitantly reduced levels of Treg cells. In this genetic background, 
either DHA supplementation or in vivo injection of RvD1 in anti-CD3 treated mice 
reduced the activation of TH1 and TH17 cells and restored Treg cell numbers. In line 
with this, it has also been shown that deletion or pharmacological inhibition of SPM-
generating 12/15-lipoxygenase regulated murine and human dendritic cell maturation 
and activation, favoring TH17 differentiation of CD4+ T cells (38), thus highlighting 
the critical role for SPMs in modulating T helper responses. The recent identification 
of SPMs in human secondary lymphoid organs (11), where most naïve-to-effector or 
iTreg differentiation happens, provides in vivo relevance of our findings. Of note, the 
expression of GPR32 and ALX/FPR2, the RvD1 receptors, by all T-cell subsets 
suggests that these receptors are involved in DHA-derived SPMs-induced effects on 
cell-mediated adaptive immunity. Interestingly, both receptors seemed to be involved 
in RvD1 signaling on both TH1 and TH17 cells independently of their relative 
expression, while GPR32 appeared to specifically mediate the effects of RvD1 on 
Treg cells. On the other hand, TH2 cells, which were not modulated by SPMs, was the 
only T cell subset to display no variation in the expression of any of these receptors 
compared to their TH0 precursors. Furthermore, the finding that SPMs preserve cell 
viability and proliferation while modulating pro-inflammatory responses is of note, 
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because it rules out the possibility that the observed immunomodulation of T cells is 
caused by SPM-induced cell death.  
Current clinical research is increasingly directed to the possibility of interfering with 
the functions of TH cells. Thus the finding that natural endogenous mediators like 
SPMs (i.e. RvD1, RvD2 and MaR1) exert a non-cytotoxic regulatory role on cells 
central to induction of autoimmunity represents a promising beginning for a new 
avenue of research. These results suggest that SPMs might possibly act on the balance 
between pathogenic TH1/TH17 and tolerogenic Treg cells, which is typically altered 
during chronic inflammatory and autoimmune diseases. This study, schematically 
summarized in Fig 7, extends the original paradigm whereby the SPMs found in the 
resolving exudates not only stimulate signs of resolution – terminating acute 
inflammation and restoring homeostasis (4) - but as reported herein can also modulate 
adaptive immunity. 
 
 
MATERIALS AND METHODS  
Study Design  
This is an experimental laboratory study performed with human blood samples (n= 
40) and animals (n=26). The objective was to study the role of specific specialized 
pro-resolving lipid mediators (Resolvin D1, Resolvin D2 and Maresin 1) on activation 
and differentiation of T cell subsets with the translational perspective to gain insights 
into the possibility that such bioactive lipids could regulate adaptive immunity and 
thus control T-cell mediated chronic inflammatory processes. All the healthy donors 
gave their written informed consent to the study. In vivo studies were carried out with 
ethical permission from the Animal Ethics Committee of the North Stockholm region, 
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Sweden. The number of replicates is indicated for each experiment in the respective 
figure legends. Mechanistic studies on cells from healthy blood donors were 
performed with in vitro assays without blinding or randomization. 
 
Materials 
RvD1 (7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid), RvD2 
(7S,16R,17S-trihydroxy-4Z,8E,10Z,12E,14E,19Z-docosahexaenoic acid), AT-RvD3 
(4S,11,17R-trihydroxydocosa-5Z,7,9,13,15E,19Z-hexaenoic acid), MaR1 (7R,14S-
dihydroxy-docosa-4Z,8E,10E,12Z,16Z,19Z-hexaenoic acid) were prepared by total 
organic synthesis as essentially described (39-42) or purchased from Cayman 
Chemical.  
 
Peripheral blood cells isolation and purification of naïve CD4+ T lymphocytes 
Peripheral blood mononuclear cells (PBMCs) were isolated after venous puncture 
from healthy donors, and were separated by density gradient over Ficoll-Hypaque 
(Amersham Biosciences). CD4+ T lymphocytes were purified by immuno-magnetic 
depletion with the human CD4+ T Cell Isolation Kit II (Miltenyi Biotec), and were 
purified by means of negative selection through AutoMACS Pro Separator (Miltenyi 
Biotec). Briefly, effector and memory T cells, NK cells, B cells, dendritic cells, and 
granulocytes were indirectly labeled using a cocktail of biotin-conjugated antibodies 
and anti-biotin magnetic microbeads. Highly purified unlabeled naïve CD4+ T cells 
(CD4+CD45RA+CD27+CD45RO-) were obtained by depletion of the magnetically 
labeled cells and had a purity of over 95%, which was confirmed by flow cytometry. 
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Flow cytometry  
In order to measure the intracellular cytokine levels, secretion was inhibited by adding 
1 µg/ml brefeldin A (Sigma-Aldrich), 5 hours before the end of stimulation with 
either PMA/Ionomycin or Dynabeads CD3/CD28 T Cell Expander (one bead per cell; 
Invitrogen) (16). At the end of the incubation, cells were stained at cell surface with 
e780-conjugated anti-CD3 (eBiosciences), PerCP5.5-conjugated anti-CD4 
(eBiosciences), Brilliant Violet-conjugated anti-CD8 (Biolegend), made permeable 
with Cytofix/Cytoperm reagents (BD Biosciences), and then stained intracellularly 
with Phycoerythrin-Cy7-conjugated anti-TNF-α (eBiosciences), Allophycocyanin 
(APC)-conjugated anti-IFN-γ (eBiosciences), Phycoerythrin (PE)-conjugated anti-IL-
17 (eBiosciences), anti-PercP5.5-conjugated anti-IL-2 (Biolegend), Brilliant Violet 
421-conjugated IL-4 (eBioscience) and Fluorescein isothiocyanate (FITC)-conjugated 
anti-Granzyme B in 0.5% saponin, at RT for 30 min. In some experiments, cells were 
also stained at cell surface with PE-conjugated anti-FasL (Miltenyi Biotec), APC-
conjugated anti-PD-1 (eBioscience) and PE-conjugated anti-CTLA-4 (Miltenyi 
Biotec). Intracellular cytokines were analyzed by flow cytometry in a FACS-Cyan 
ADP (Beckman Coulter). For each analysis, at least 300,000 events were acquired 
gating on Pacific Orange-conjugated Live/Dead negative cells. In some experiments 
PBMCs were pre-incubated for 30 min with anti-GPR32 (2 µg/ml; clone GTX71225, 
GeneTex) and/or anti-FPR2/ALX (2 µg/ml, clone FN-1D6-A1, Genovac, Freiburg, 
Germany) prior to incubation with vehicle or 10 nmol/L RvD1 and to stimulation with 
Dynabeads CD3/CD28 T Cell Expander (one bead per cell; Invitrogen). The list of 
antibodies used for flow cytometry and their dilution is detailed in Table S1. 
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Detection of apoptotic and necrotic cells 
Apoptotic and necrotic cells were detected using Annexin-V-FITC and propidium 
iodide (PI) staining (eBioscience), respectively. Cells were washed twice in in PBS 
followed by re-suspension in Binding Buffer (Annexin-V Kit, eBioscience) and then 
incubated with 5µl of Annexin-V-FITC for 15 min at RT. Cell were then extensively 
washed with Binding Buffer and 5µl of PI was added and cells analyzed within 2 
hours on a FACS-Cyan ADP (Beckman Coulter).  
 
Proliferation Assay 
CD3+ T cells were isolated through positive selection with AutoMACS Pro Separator 
and 10X106 cells were labeled with CFSE at a final concentration of 5$µM for 10$min 
at 37$°C in agitation. Then, cells were washed twice with PBS/10% FBS, suspended 
in culture media and analyzed immediately on a FACS-Cyan ADP (Beckman 
Coulter). Analysis of cells immediately after CFSE labeling indicated a labeling 
efficiency higher than 99%. Cell proliferation was followed by flow cytometry at day 
2 and 4 upon stimulation with Dynabeads CD3/CD28 T Cell Expander in presence or 
absence of 10 nmol/L RvD1, RvD2 and MaR1.  
 
T helper cell differentiation assay 
For TH1 and TH17 polarization of T cells, highly purified naïve CD4+ T cells were 
cultured in round bottom 96-well plates (Falcon) at a density of 5x104 cells at 37°C in 
200µl final volumes of X-VIVO 15 medium with Dynabeads CD3/CD28 T Cell 
Expander and under TH1-, TH2- and TH17-polarizing conditions in presence or 
absence of RvD1, RvD2 or MaR1 (10 nmol/L). The following human recombinant 
cytokines were used:  for TH1 polarization, 10ng/ml IL-12 (Miltenyi Biotech); and for 
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TH17 polarization, 10ng/ml IL-1β, 20ng/ml IL-6, 100ng/ml IL-23, and 1ng/ml TGF-β 
(Miltenyi Biotech). After 5 days, cells were collected and washed extensively and 
their viability was determined by trypan blue exclusion. Cells (1x106 cells/ml) were 
re-stimulated for 6h (for flow cytometry) or 24h (for ELISA and qRT-PCR) with 
Dynabeads CD3/CD28 T Cell Expander (one bead per cell). Cultures were 
supplemented with RvD1, RvD2 or MaR1 every other day for 5d for flow cytometry 
analysis and then were re-stimulated with CD3/CD28 beads for 24h for ELISA and 
qRT-PCR. For TH2 polarization, naïve CD4+ T cells were kept under polarizing 
conditions using 25ng/ml IL-4 (Miltenyi Biotec) and Dynabeads CD3/CD28. Cells 
were extensively washed and re-stimulated with CD3/CD28 beads every 3 days with 
fresh medium plus IL-4 and 20ng/ml IL-2 (Miltenyi Biotec) up to day 12. After 12 
days cells were collected for ELISA or qRT-PCR or re-stimulated for 6h with 
100nmol/l PMA/Ionomycin for intracellular staining. In some experiments TH1, TH17 
and iTreg cells were incubated for 30 min with anti-GPR32 (2 µg/ml) and anti-
FPR2/ALX (2 µg/ml) antibodies, alone or in combination, washed with complete 
medium, subsequently treated with vehicle or 10 nmol/L RvD1 and then stimulated 
with CD3/CD28 beads. 
 
Generation of induced Treg cells 
Highly purified naïve CD4+ T cells were cultured in round bottom 96-well plates 
(Falcon) at a density of 5x104 cells at 37°C in 200µl final volumes of X-VIVO 15 
medium in presence of Dynabeads CD3/CD28 T Cell Expander (one bead per cell; 
Invitrogen), TGF-β (2 ng/ml; Miltenyi Biotec) and IL-2 (20 U/ml), in the presence or 
absence of RvD1, RvD2, or MaR1 (10 nmol/L). Cultures were supplemented with 
SPMs every other day for 5 d. 
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ELISA  
Cytokine content was determined by standard 2-site sandwich enzyme-linked 
immunosorbent assays (ELISA), using available commercial kits for IFN-γ and IL-17 
(eBioscience), as previously reported (43) and through Multiplex Bead-based 
Luminex Assay for measurement of IL-4 and IL-10 (R&D Systems). 
 
qRT-PCR 
Total RNA was extracted with an RNeasy Micro kit (Qiagen). A mixture containing 
random hexamers, oligo(dT)15 (Promega) and SuperScript II Reverse Transcriptase 
(Invitrogen) was used for cDNA synthesis. Transcripts were quantified by real-time 
quantitative PCR on an ABI PRISM 7900 sequence detector (Applied Biosystems) 
with Applied Biosystems predesigned TaqMan Gene Expression Assays and Absolute 
QPCR ROX mix (Thermo Fisher Scientific). The following probes were used 
(Applied Biosystems, assay identification numbers in parentheses): T-bet 
(Hs00203436_m1), RORc (Hs01076112_m1), GATA-3 (Hs00231122), GPR32 
(Hs01102536_s1) and FPR2 (Hs02759175_s1). For each sample, mRNA abundance 
was normalized to the amount of ribosomal protein L34 (Hs00241560_m1). 
 
Immunoblotting 
Purified and polarized TH0, TH1, TH2, TH17 and iTreg cells were lysed with lysis 
buffer and cell homogenates were subjected to 10% SDS–PAGE (50 µg/lane) under 
reducing conditions. Gels were then electroblotted onto 0.45-µm nitrocellulose filters 
(Bio-Rad, Hercules, CA, USA) and were incubated with primary anti-GPR32 
polyclonal mouse antibody (1:500, clone GTX71225, GeneTex), anti-ALX/FPR2 
monoclonal rabbit antibody (1:500, clone FN-1D6-A1, Genovac) or with anti-β-actin 
! 21!
monoclonal mouse antibody (1:10000, Bio-Rad), and then with secondary goat-anti-
rabbit polyclonal antibody (1:2000, Santa Cruz Biotechnologies) for GPR32 and goat-
anti-mouse polyclonal antibody (1:2000 for ALX and 1:10000 for β-actin). 
 
Elovl2 knock out animals and in vivo experiments 
Elovl2-/- mice were generated as described previously (16). All animals were housed 
at room temperature and maintained on a 12 h light/ dark cycle. Adult mice were fed 
standard chow DHA-free diet (10% kcal fat, D12450H, Research Diets, New 
Brunswick, NJ, USA) or DHA-enriched (10% kcal fat, 14% DHA, D13021002, 
Research Diets, New Brunswick, NJ, USA), according to the experimental groups. 
All animals were fed ad libitum and had free access to water. At the end of the study, 
animals were euthanized with CO2 and cervical dislocation. For in vivo experiments, 
mice were pretreated intraperitoneally (ip) with 100 ng RvD1 for 15 min and then 
injected with 50 µg of anti-CD3 (Biolegend, Armenian hamster IgG, clone 145-
2C11). Blood samples were recovered 3 h after antibody injection and a cell 
suspension was prepared for flow cytometry analysis. 
 
Statistical analysis 
All data were expressed as means ± SEM. Differences between groups were 
compared using Student’s t-test (two groups) or one-way ANOVA (multiple groups) 
followed by a post hoc Bonferroni test. The criterion for statistical significance was p 
< 0.05 or less. All statistical analyses were performed with GraphPad Prism. FACS 
analysis was performed using the FlowJo analysis program (Treestar, Ashland, OR).  
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SUPPLEMENTAL MATERIAL 
 
Fig. S1. AT-RvD3 dose-dependently reduces TNF- and Resolvin D1, D2 and 
Maresin 1 do not affect long-term cell death in both CD8+ and CD4+ T cells. 
 
Fig. S2. Resolvin D1, D2 and Maresin 1 do not affect TH0 cells. 
 
Fig. S3. Gating strategy for Treg identification. 
 
Table S1. Antibodies used for T cell surface staining and for analysis of intracellular 
cytokine production. 
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Figure legends 
 
Fig. 1. Pro-resolving lipid mediators dose-dependently reduce TNF-α from CD8+ and 
CD4+ T cells. (A) Chemical structures of the SPMs Resolvin D1, Resolvin D2 and 
Maresin 1. (B) PBMCs (1x106 cells/well) were left untreated (Veh) or treated with 
different concentrations (1-100 nmol/L) of SPMs (RvD1, RvD2, and MaR1) for 30 
min. Cells were then stimulated with PMA/ionomycin for 6 hours, stained at cell 
surface and intracellularly, and analyzed by flow cytometry (C) A representative 
cytofluorimetric plot of the gating strategy for TNF-α evaluation from CD8+ and 
CD4+ T cells. PBMCs were appropriately gated according to physical parameters. (D) 
Percentages of intracellular cytokine production in both CD8+ and CD4+ T cells. 
Data are shown as means ± SEM of four independent experiments. *p <0.05 (one-way 
Anova). 
 
Fig. 2. Pro-resolving lipid mediators reduce CD8+ and CD4+ T cell responses. 
PBMCs (1x106 cells/well) were left untreated or treated with 10 nmol/L SPMs 
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(RvD1, RvD2, and MaR1) for 30 min. Cells were then stimulated with 
PMA/ionomycin for 6 hours (A-B) or with anti-CD3/CD28 beads (C-D), stained at 
cell surface and intracellularly, and analyzed by flow cytometry, as detailed in 
Materials and Methods. Percentages of intracellular production of TNF-α and IFN-γ 
from CD8+ and of TNF-α, IFN-γ and IL-17 from CD4+ T cells are shown as means ± 
SEM of eight independent experiments. *p <0.05, **p <0.01, ***p <0.001 (one-way 
Anova). 
 
Fig. 3. Pro-resolving lipid mediators inhibit IL-2 production from TCR-activated 
CD8+ and CD4+ T cell without affecting their viability. PBMCs (1x106 cells/well) 
were left untreated or treated with 10 nmol/L RvD1, RvD2 and MaR1 for 30 min. 
Cells were then stimulated with anti-CD3/anti-CD28 for 8 hours, stained at cell 
surface and intracellularly, and analyzed by flow cytometry. (A) Percentages of 
intracellular production of IL-2 from CD8+ and CD4+ T cells are shown as means ± 
SEM of six independent experiments. *p <0.05 (one-way Anova). (B) Cell death of 
CD8+ and CD4+ T cells after stimulation with anti-CD3/CD28 beads through 
staining for Annexin V and PI flow cytometry analysis. The percentage of Annexin 
V+/PI-cells (early apoptotic cells) and Annexin V+ cells (total apoptotic cells) is 
reported in the cumulative graph. Data are shown as means ± SEM of four 
independent experiments. (C) Cell proliferation of CD3+ T cells after stimulation 
with anti-CD3/CD28 beads (day 4) shown by CSFE dilution (D) Surface expression 
of FASL, PD-1 and CTLA-4 in CD3+ T cells after stimulation with anti-CD3/CD28. 
A representative experiment (of four independent experiments) of receptor expression 
is shown (in grey the isotype is shown).  
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Fig. 4. Pro-resolving lipid mediators affect T-helper cells polarization. (A) Schematic 
representation of TH1, TH17 and TH2 generation. (B) Percentages of intracellular 
cytokine production from polarized TH1, TH17 and TH2 cells in presence or absence 
of RvD1, RvD2 or MaR1 10 nmol/L, assessed after 6 h of restimulation with anti-
CD3/CD28. Data are shown as means ± SEM of six independent experiments. *p 
<0.05, **p <0.01 (one-way Anova). (C) ELISA of IFN-γ, IL-17 and IL-4 in 
supernatants of TH1, TH17 and TH2 cells polarized in presence or absence of RvD1, 
RvD2 or MaR1 nmol/L, measured after 24 h of restimulation with anti-CD3/CD28. 
Data are shown as means ± SEM of six independent experiments. *p <0.05, **p 
<0.01 (one-way Anova). (D) qRT-PCR analysis of the expression of T-bet, RORc and 
GATA-3 in TH1, TH17 and TH2 cells. Cycling threshold values are normalized to 
those of mRNA encoding ribosomal protein L34, and data are normalized to the 
maximum value obtained for each donor. Data are expressed as arbitrary units (A.U.) 
and are shown as means ± SEM of four independent experiments. (E) Percentages of 
intracellular production of IFN-γ and IL-17 from CD4+ T cells of splenocytes 
obtained from wild type (WT), Elovl2 knock out (Elovl2-/-) and Elovl2-/- + DHA 
mice. Data are shown as means ± SEM of 4 different mice per experimental group 
and performed in duplicate. *p <0.05 versus WT, #p <0.05 versus Elovl2-/- (one-way 
Anova). (F) Percentages of intracellular production of IFN-γ and IL-17 from 
peripheral blood CD4+ T cells obtained from wild type (WT) and Elovl2 knock out 
(Elovl2-/-) mice injected intraperitoneally with 100 ng RvD1 for 15 min and then with 
50 µg of anti-CD3 for 3h. Data are shown as means ± SEM of 4 different mice. *p 
<0.05 versus WT or Elovl2-/- (t-test). 
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Fig. 5. Pro-resolving lipid mediators promote de novo generation of Foxp3-expressing 
Treg cells. (A) Schematic representation of iTreg generation. (B) Flow cytometry 
analysis of iTreg cells gated on CD4+CD25high and CD127- cells and expressing 
Foxp3, CTLA-4 and Granzyme B, and ELISA of IL-10 in supernatants of iTreg cells. 
Data are shown as means ± SEM of four independent experiments. *p <0.05 versus 
iTreg, **p <0.01 versus iTreg (one-way Anova). (C) Percentages of intracellular 
expression of Foxp3 in CD25high CD4+ T cells of splenocytes obtained from wild 
type (WT), Elovl2 knock out (Elovl2-/-) and Elovl2-/- + DHA mice. Data are shown as 
means ± SEM of 5 different mice. *p <0.05 versus WT, #p <0.05 versus Elovl2-/- 
(one-way Anova). 
 
Fig. 6. The effects of Pro-resolving lipid mediators on T cells are mediated by GPR32 
and ALX/FPR2 receptors. (A) qRT-PCR analysis, immunoblotting of GPR32 and 
ALX/FPR2 in polarized TH0, TH1, TH2, TH17 and iTreg, as detailed in Materials and 
Methods. Data are shown as means ± SEM of four independent experiments. *p <0.05 
versus TH0 (one-way Anova for TH1, TH2, TH17 and t-test for iTreg). A flow 
cytometry representative analysis of GPR32 and ALX/FPR2 is shown in resting and 
anti-CD3/CD28-activated total peripheral CD3+ T cells (B-C) Intracellular cytokine 
production from CD4+ and CD8+ T cells as well as from polarized TH1, TH17 and 
iTreg pre-treated with neutralizing antibodies against GPR32 or ALX/FPR2 (alone or 
in combination, 2 µg/ml) in presence of RvD1 and following anti-CD3/CD28 
stimulation for 8 hours. Data are shown as means ± SEM of four independent 
experiments. *p <0.05 versus anti-CD3/CD28-activated cells; #p <0.05 versus RvD1-
treated cells (one-way Anova). 
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Fig. 7. Schematic representation of SPMs effects on T cell subsets. Here we 
demonstrate that RvD1, RvD2 and MaR1 significantly reduce the release of pro-
inflammatory cytokines in both activated CD8+ T cells and in already committed TH1 
and TH17 CD4+ cell subsets engaging both GPR32 ALX/FPR2 receptors. 
Furthermore, RvD1, RvD2 and MaR1 prevent de novo generation of TH1 and TH17 
from CD4+ naïve T cells via both receptors, while favoring that of iTreg cells through 
only GPR32. Foxp3, forkhead box p3; IFN-γ, interferon-γ; IL-17, interleukin-17; 
MaR, maresin; RORγt, RAR-related orphan receptor γ; Rv, resolvin; T-bet, T-box 
expressed in T-cells; TH, T-helper; TNF-α, tumor necrosis factor-α. 
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Fig. S1. AT-RvD3 dose-dependently reduces TNF-α and Resolvin D1, D2 and 
Maresin 1 do not affect long-term cell death in both CD8+ and CD4+ T cells (A) 
PBMCs (1x106 cells/well) were left untreated (Veh) or treated with different 
concentrations (1-100 nmol/L) of AT-RvD3 for 30 min. Cells were then stimulated 
with PMA/ionomycin for 6 hours, stained at cell surface and intracellularly, and 
analyzed by flow cytometry. Data represent percentages of intracellular cytokine 
production in both CD8+ and CD4+ T cells and are shown as means ± SEM of four 
independent experiments. *p <0.05 (one-way Anova). (B) Cell death of CD8+ and 
CD4+ T cells stimulated with anti-CD3/CD28 beads for 24 h by means of Annexin V 
staining. The percentage of Annexin V positive  cells (total apoptotic cells) is reported and 
data are shown as means ± SEM of four independent experiments. (C) Cell death of 
resting CD8+ and CD4+ T cells by means of Annexin V staining.  The percentage of 
Annexin V positive  cells (total apoptotic cells) is reported and data are shown as means ± 
SEM of four independent experiments.  
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Fig. S2. Resolvin D1, D2 and Maresin 1 do not affect TH0 cells. Percentages of 
intracellular cytokine production of IFN-γ, IL-17 and IL-4 from polarized TH0 cells 
incubated in presence or absence of RvD1, RvD2 or MaR1 (10 nmol/L) assessed after 
6 h of restimulation with anti-CD3/CD28. Data are shown as means ± SEM of four 
independent experiments. 
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Fig.% S3.! Gating! strategy! for! Treg! identification.! Blood!was! collected! from!WT! and! Elovl2</<!
mice!after!3!h!of! in!vivo! injection!of!50 µg anti<CD3!antibody!or!100!ng!RvD1! (alone!or! in!
combination).! Peripheral! blood! mononuclear! cells! (PBMCs)! (1X106)! were! stained! at! cell!
surface!with!e780<conjugated!CD4!and!PE<conjugated!CD25!antibodies,!permeabilized!with!
4%!formaldehyde!and!then!intracellularly!stained!with!APC<conjugated!Foxp3!antibody.!Cells!
were!gated!on!CD4!positive!cells!and!then!Treg!cells!were!identified!gating!on!CD25!high!and!
Foxp3!expressing!cells.!Data!are! representative!of!a! single! staining!out!of!5!different!mice!
per!experimental!group.!
!
 
Fig. S4. Schematic representation of SPMs checkpoints on the regulation of acute and 
chronic inflammatory processes. During the acute inflammation, the site of infection features 
a massive infiltration of innate immune cells (e.g. neutrophils and monocytes) that trigger 
inflammatory processes through the production of cytokines, chemokines and omega-6 
derivates, (e.g. prostaglandins, prostacyclins, leukotrienes and thromboxanes) and reactive 
species, that promote vasodilatation, recruitment of other neutrophils and monocytes as well 
as elimination of pathogens. In the advanced phases of acute inflammation, neutrophils and 
resolving macrophages undergo a molecular reconfiguration of their lipid mediators’ profile, 
and start producing SPMs (including RvD1, RvD2 and MaR1) that promote the resolution of 
inflammation, which is characterized by the induction of apoptosis in neutrophils and 
clearance of cellular debris. Here we demonstrate that RvD1, RvD2 and MaR1 can also act on 
adaptive immune cells that play a central role later, during chronic inflammation, significantly 
reducing the release of pro-inflammatory cytokines in activated CD8+ T cells as well as in 
already committed TH1 and TH17 CD4+ cell subsets engaging both GPR32 ALX/FPR2 
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receptors. Furthermore, RvD1, RvD2 and MaR1 prevent de novo generation of TH1 and TH17 
from CD4+ naïve T cells via both receptors, while favoring that of iTreg cells through only 
GPR32. Hence, in the event that the acute inflammation is not properly resolved, the SPMs 
that reside in the resolving exudate, might be also involved in limiting the chronic 
inflammatory responses acting on the balance between highly pathogenic TH1/TH17 and 
regulatory iTreg cells. Of note, adaptive immunity can also regulate several functions of 
innate immunity, thus establishing a complex network, typical of several pathophysiological 
conditions (such as autoimmunity). Foxp3, forkhead box p3; IFN-γ, interferon-γ; IL-17, 
interleukin-17; MaR, maresin; PMN, polymorphonucleate cells; PUFA, polyunsaturated fatty 
acids; RORγt, RAR-related orphan receptor γ; Rv, resolvin; SPMs, specialized pro-resolving 
lipid mediators; T-bet, T-box expressed in T-cells; TH, T-helper; TNF-α, tumor necrosis 
factor-α. 
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Table S1. Antibodies used for T cell surface staining and for analysis of intracellular cytokine 
production. 
Antibody Manufacturer Dilution 
CD4 e780 eBiosciences (San Diego, CA) 1:100 
CD8 Brilliant Violet Biolegend (San Diego, CA) 1:100 
FasL PE Miltenyi Biotec. (Bergisch Gladbach, Germany) 1:60 
PD-1 APC eBioscience 1:50 
CTLA4 PE Miltenyi Biotec. 1:60 
TNF-α PE-Cy7 eBiosciences 1:100 
IFN-γ  APC eBiosciences 1:100 
IL-17 PE eBiosciences 1:50 
IL-2 PercP5.5 Biolegend 1:50 
IL-4 BV421 Biolegend 1:50 
Granzyme FITC eBioscience 1:30 
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